Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen Vaccine in Esophagus Cancer Patients
NCT05307835Phase 1Active, not recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2021
- Primary completion
- Jun 2026
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iNeo-Vac-P01 in esophageal cancer, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Adverse Events at 1 year and Relapse Free Survival Rate at 1 year. Started Dec 2021; status: active, not recruiting.
02
Drugs
iNeo-Vac-P01
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT05307835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05307835.